Last week, I had the opportunity to join business leaders in Washington, D.C., as part of the U.S. Business Action to End HIV—a cross-sector coalition working to accelerate progress toward ending the HIV epidemic in the United States.
Over the course of two days on Capitol Hill, myself and fellow coalition members, including Gilead Sciences, Healthvana, Match Group, Mercer, Merck, MISTR, and ViiV Healthcare, met with Congressional offices across both chambers. These included discussions with key leaders and staff from offices such as Rep. Buddy Carter (GA-01), Sen. Bill Cassidy (R-LA), Sen. Susan Collins (R-ME), and Rep. Andy Harris (MD-01), among others.
The goal: underscore the importance of continued federal investment in HIV prevention and care programs—especially the Ryan White HIV/AIDS Program and the Ending the HIV Epidemic (EHE) initiative launched in 2019.
These meetings were an important moment for the private sector to reinforce our commitment to ending HIV by 2030. We see this not only as a public health imperative, but as a business issue. A healthier, more informed population leads to a stronger workforce and a more resilient economy.”
Throughout the visit, the coalition shared compelling data about the cost-effectiveness and life-saving potential of HIV prevention investments. For example, research shows that preventing just one HIV transmission can save over $850,000 in lifetime healthcare costs—and continued federal support for the EHE initiative could prevent up to 255,000 new transmissions, amounting to $216 billion in savings.
Why This Matters to Alchemy
At Alchemy, we believe that health equity and innovation go hand in hand. We’re committed to supporting workplace wellness and improving access to healthcare—not just through our in-house pharmacies, but through broad partnerships and advocacy.
Our participation in the U.S. Business Action to End HIV reflects our belief in cross-sector collaboration to drive systemic change. From safeguarding access to preventive medications like PrEP to sustaining Medicaid coverage for people living with HIV, we see continued federal investment as essential to the national strategy.
“Progress takes partnership,” said Ramin Bastani, CEO of Healthvana and fellow Coalition member. “This coalition proves what’s possible when business leaders and lawmakers come together.”
We’re proud to stand alongside business leaders who share our commitment to a healthier future—and grateful to the members of Congress who welcomed our perspectives.
Next Steps
As Congress considers FY26 funding priorities, Alchemy will continue to advocate for strong public-private partnerships that protect access to HIV care and prevention. We believe that with the right policies, investment, and innovation, ending the HIV epidemic is not only possible—but inevitable.
To learn more about the U.S. Business Action to End HIV and how your organization can get involved, visit https://www.businessactiontoendhiv.org
.png)
.png)
.png)
